nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—liver cancer	0.694	1	CbGaD
Valsartan—Irbesartan—JUN—liver cancer	0.0064	0.913	CrCbGaD
Valsartan—Rhabdomyolysis—Sorafenib—liver cancer	0.0035	0.0196	CcSEcCtD
Valsartan—Drug interaction—Sorafenib—liver cancer	0.00334	0.0187	CcSEcCtD
Valsartan—Blood pressure increased—Sorafenib—liver cancer	0.00309	0.0174	CcSEcCtD
Valsartan—Renal failure acute—Sorafenib—liver cancer	0.00243	0.0137	CcSEcCtD
Valsartan—Myositis—Epirubicin—liver cancer	0.00233	0.0131	CcSEcCtD
Valsartan—Cardiac failure—Sorafenib—liver cancer	0.0023	0.0129	CcSEcCtD
Valsartan—Hyponatraemia—Sorafenib—liver cancer	0.00226	0.0127	CcSEcCtD
Valsartan—Myositis—Doxorubicin—liver cancer	0.00216	0.0121	CcSEcCtD
Valsartan—Abdominal pain upper—Sorafenib—liver cancer	0.00205	0.0115	CcSEcCtD
Valsartan—Serum creatinine increased—Epirubicin—liver cancer	0.00186	0.0104	CcSEcCtD
Valsartan—Neutropenia—Sorafenib—liver cancer	0.00182	0.0102	CcSEcCtD
Valsartan—Erectile dysfunction—Sorafenib—liver cancer	0.00179	0.01	CcSEcCtD
Valsartan—Infestation NOS—Sorafenib—liver cancer	0.00173	0.00971	CcSEcCtD
Valsartan—Infestation—Sorafenib—liver cancer	0.00173	0.00971	CcSEcCtD
Valsartan—Serum creatinine increased—Doxorubicin—liver cancer	0.00172	0.00965	CcSEcCtD
Valsartan—Renal failure—Sorafenib—liver cancer	0.0017	0.00955	CcSEcCtD
Valsartan—Epistaxis—Sorafenib—liver cancer	0.00163	0.00916	CcSEcCtD
Valsartan—Haemoglobin—Sorafenib—liver cancer	0.00156	0.00876	CcSEcCtD
Valsartan—Haemorrhage—Sorafenib—liver cancer	0.00155	0.00872	CcSEcCtD
Valsartan—Urinary tract disorder—Sorafenib—liver cancer	0.00153	0.00861	CcSEcCtD
Valsartan—Connective tissue disorder—Sorafenib—liver cancer	0.00153	0.00857	CcSEcCtD
Valsartan—Urethral disorder—Sorafenib—liver cancer	0.00152	0.00855	CcSEcCtD
Valsartan—Cardiac disorder—Sorafenib—liver cancer	0.00144	0.00809	CcSEcCtD
Valsartan—Ageusia—Epirubicin—liver cancer	0.00141	0.00792	CcSEcCtD
Valsartan—Angiopathy—Sorafenib—liver cancer	0.00141	0.00791	CcSEcCtD
Valsartan—Immune system disorder—Sorafenib—liver cancer	0.0014	0.00788	CcSEcCtD
Valsartan—Mediastinal disorder—Sorafenib—liver cancer	0.0014	0.00786	CcSEcCtD
Valsartan—Alopecia—Sorafenib—liver cancer	0.00137	0.00771	CcSEcCtD
Valsartan—Mental disorder—Sorafenib—liver cancer	0.00136	0.00764	CcSEcCtD
Valsartan—Malnutrition—Sorafenib—liver cancer	0.00135	0.00759	CcSEcCtD
Valsartan—Dysgeusia—Sorafenib—liver cancer	0.00132	0.00743	CcSEcCtD
Valsartan—Ageusia—Doxorubicin—liver cancer	0.00131	0.00733	CcSEcCtD
Valsartan—Muscle spasms—Sorafenib—liver cancer	0.0013	0.0073	CcSEcCtD
Valsartan—Viral infection—Epirubicin—liver cancer	0.00127	0.0071	CcSEcCtD
Valsartan—Angioedema—Sorafenib—liver cancer	0.00124	0.00694	CcSEcCtD
Valsartan—Syncope—Sorafenib—liver cancer	0.00121	0.00681	CcSEcCtD
Valsartan—Loss of consciousness—Sorafenib—liver cancer	0.00119	0.00667	CcSEcCtD
Valsartan—Cough—Sorafenib—liver cancer	0.00118	0.00662	CcSEcCtD
Valsartan—Viral infection—Doxorubicin—liver cancer	0.00117	0.00657	CcSEcCtD
Valsartan—Myalgia—Sorafenib—liver cancer	0.00115	0.00646	CcSEcCtD
Valsartan—Arthralgia—Sorafenib—liver cancer	0.00115	0.00646	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00114	0.00642	CcSEcCtD
Valsartan—Dry mouth—Sorafenib—liver cancer	0.00113	0.00632	CcSEcCtD
Valsartan—Hyperkalaemia—Epirubicin—liver cancer	0.00112	0.00631	CcSEcCtD
Valsartan—Anaphylactic shock—Sorafenib—liver cancer	0.0011	0.0062	CcSEcCtD
Valsartan—Infection—Sorafenib—liver cancer	0.0011	0.00615	CcSEcCtD
Valsartan—Shock—Sorafenib—liver cancer	0.00109	0.0061	CcSEcCtD
Valsartan—Nervous system disorder—Sorafenib—liver cancer	0.00108	0.00608	CcSEcCtD
Valsartan—Thrombocytopenia—Sorafenib—liver cancer	0.00108	0.00607	CcSEcCtD
Valsartan—Blood urea increased—Epirubicin—liver cancer	0.00108	0.00606	CcSEcCtD
Valsartan—Skin disorder—Sorafenib—liver cancer	0.00107	0.00602	CcSEcCtD
Valsartan—Anorexia—Sorafenib—liver cancer	0.00105	0.00591	CcSEcCtD
Valsartan—Hyperkalaemia—Doxorubicin—liver cancer	0.00104	0.00583	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00101	0.00564	CcSEcCtD
Valsartan—Blood urea increased—Doxorubicin—liver cancer	0.000999	0.00561	CcSEcCtD
Valsartan—Dyspnoea—Sorafenib—liver cancer	0.000984	0.00552	CcSEcCtD
Valsartan—Dyspepsia—Sorafenib—liver cancer	0.000972	0.00545	CcSEcCtD
Valsartan—Decreased appetite—Sorafenib—liver cancer	0.00096	0.00539	CcSEcCtD
Valsartan—Gastrointestinal disorder—Sorafenib—liver cancer	0.000953	0.00535	CcSEcCtD
Valsartan—Fatigue—Sorafenib—liver cancer	0.000952	0.00534	CcSEcCtD
Valsartan—Photosensitivity—Epirubicin—liver cancer	0.000946	0.00531	CcSEcCtD
Valsartan—Constipation—Sorafenib—liver cancer	0.000944	0.0053	CcSEcCtD
Valsartan—Gastrointestinal pain—Sorafenib—liver cancer	0.000903	0.00507	CcSEcCtD
Valsartan—Renal failure acute—Epirubicin—liver cancer	0.000899	0.00505	CcSEcCtD
Valsartan—Urticaria—Sorafenib—liver cancer	0.000877	0.00492	CcSEcCtD
Valsartan—Photosensitivity—Doxorubicin—liver cancer	0.000875	0.00491	CcSEcCtD
Valsartan—Abdominal pain—Sorafenib—liver cancer	0.000873	0.0049	CcSEcCtD
Valsartan—Renal impairment—Epirubicin—liver cancer	0.000872	0.00489	CcSEcCtD
Valsartan—Dermatitis bullous—Epirubicin—liver cancer	0.000869	0.00487	CcSEcCtD
Valsartan—Cardiac failure—Epirubicin—liver cancer	0.000851	0.00477	CcSEcCtD
Valsartan—Hyponatraemia—Epirubicin—liver cancer	0.000834	0.00468	CcSEcCtD
Valsartan—Renal failure acute—Doxorubicin—liver cancer	0.000832	0.00467	CcSEcCtD
Valsartan—Hypersensitivity—Sorafenib—liver cancer	0.000813	0.00456	CcSEcCtD
Valsartan—Renal impairment—Doxorubicin—liver cancer	0.000807	0.00453	CcSEcCtD
Valsartan—Dermatitis bullous—Doxorubicin—liver cancer	0.000804	0.00451	CcSEcCtD
Valsartan—Asthenia—Sorafenib—liver cancer	0.000792	0.00444	CcSEcCtD
Valsartan—Cardiac failure—Doxorubicin—liver cancer	0.000787	0.00442	CcSEcCtD
Valsartan—Pruritus—Sorafenib—liver cancer	0.000781	0.00438	CcSEcCtD
Valsartan—Blood creatinine increased—Epirubicin—liver cancer	0.000778	0.00436	CcSEcCtD
Valsartan—Hyponatraemia—Doxorubicin—liver cancer	0.000771	0.00433	CcSEcCtD
Valsartan—Orthostatic hypotension—Epirubicin—liver cancer	0.000758	0.00425	CcSEcCtD
Valsartan—Abdominal pain upper—Epirubicin—liver cancer	0.000758	0.00425	CcSEcCtD
Valsartan—Diarrhoea—Sorafenib—liver cancer	0.000755	0.00424	CcSEcCtD
Valsartan—Muscular weakness—Epirubicin—liver cancer	0.000732	0.00411	CcSEcCtD
Valsartan—Dizziness—Sorafenib—liver cancer	0.00073	0.0041	CcSEcCtD
Valsartan—Blood creatinine increased—Doxorubicin—liver cancer	0.00072	0.00404	CcSEcCtD
Valsartan—Vomiting—Sorafenib—liver cancer	0.000702	0.00394	CcSEcCtD
Valsartan—Orthostatic hypotension—Doxorubicin—liver cancer	0.000702	0.00394	CcSEcCtD
Valsartan—Abdominal pain upper—Doxorubicin—liver cancer	0.000702	0.00394	CcSEcCtD
Valsartan—Rash—Sorafenib—liver cancer	0.000696	0.00391	CcSEcCtD
Valsartan—Dermatitis—Sorafenib—liver cancer	0.000696	0.0039	CcSEcCtD
Valsartan—Headache—Sorafenib—liver cancer	0.000692	0.00388	CcSEcCtD
Valsartan—Bronchitis—Epirubicin—liver cancer	0.00069	0.00387	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—liver cancer	0.000678	0.0038	CcSEcCtD
Valsartan—Neutropenia—Epirubicin—liver cancer	0.000671	0.00376	CcSEcCtD
Valsartan—Upper respiratory tract infection—Epirubicin—liver cancer	0.000667	0.00374	CcSEcCtD
Valsartan—Nausea—Sorafenib—liver cancer	0.000656	0.00368	CcSEcCtD
Valsartan—Photosensitivity reaction—Epirubicin—liver cancer	0.000655	0.00368	CcSEcCtD
Valsartan—Infestation NOS—Epirubicin—liver cancer	0.00064	0.00359	CcSEcCtD
Valsartan—Infestation—Epirubicin—liver cancer	0.00064	0.00359	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—liver cancer	0.000639	0.00358	CcSEcCtD
Valsartan—Renal failure—Epirubicin—liver cancer	0.000629	0.00353	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—liver cancer	0.000621	0.00348	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000617	0.00346	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—liver cancer	0.000606	0.0034	CcSEcCtD
Valsartan—Losartan—ALB—liver cancer	0.000606	0.0864	CrCbGaD
Valsartan—Epistaxis—Epirubicin—liver cancer	0.000603	0.00339	CcSEcCtD
Valsartan—Sinusitis—Epirubicin—liver cancer	0.0006	0.00337	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—liver cancer	0.000592	0.00332	CcSEcCtD
Valsartan—Infestation—Doxorubicin—liver cancer	0.000592	0.00332	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—liver cancer	0.000582	0.00327	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—liver cancer	0.000577	0.00324	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—liver cancer	0.000576	0.00323	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—liver cancer	0.000574	0.00322	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—liver cancer	0.000574	0.00322	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—liver cancer	0.00057	0.0032	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—liver cancer	0.000567	0.00318	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—liver cancer	0.000564	0.00317	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—liver cancer	0.000563	0.00316	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—liver cancer	0.000558	0.00313	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—liver cancer	0.000555	0.00312	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—liver cancer	0.000534	0.003	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—liver cancer	0.000533	0.00299	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—liver cancer	0.000533	0.00299	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—liver cancer	0.000531	0.00298	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—liver cancer	0.000531	0.00298	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—liver cancer	0.000527	0.00296	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—liver cancer	0.000525	0.00294	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—liver cancer	0.000522	0.00293	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—liver cancer	0.000521	0.00292	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—liver cancer	0.000521	0.00292	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—liver cancer	0.000519	0.00291	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—liver cancer	0.000518	0.0029	CcSEcCtD
Valsartan—Alopecia—Epirubicin—liver cancer	0.000508	0.00285	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—liver cancer	0.000503	0.00282	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—liver cancer	0.0005	0.00281	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—liver cancer	0.000493	0.00277	CcSEcCtD
Valsartan—Flatulence—Epirubicin—liver cancer	0.000493	0.00276	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—liver cancer	0.00049	0.00275	CcSEcCtD
Valsartan—Back pain—Epirubicin—liver cancer	0.000484	0.00271	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—liver cancer	0.000482	0.00271	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—liver cancer	0.000481	0.0027	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—liver cancer	0.00048	0.00269	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—liver cancer	0.000479	0.00269	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—liver cancer	0.000471	0.00264	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—liver cancer	0.00047	0.00263	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—liver cancer	0.000466	0.00261	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—liver cancer	0.000463	0.0026	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—liver cancer	0.000456	0.00256	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—liver cancer	0.000453	0.00254	CcSEcCtD
Valsartan—Vertigo—Epirubicin—liver cancer	0.000449	0.00252	CcSEcCtD
Valsartan—Syncope—Epirubicin—liver cancer	0.000448	0.00252	CcSEcCtD
Valsartan—Back pain—Doxorubicin—liver cancer	0.000447	0.00251	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—liver cancer	0.000445	0.0025	CcSEcCtD
Valsartan—Palpitations—Epirubicin—liver cancer	0.000442	0.00248	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—liver cancer	0.000439	0.00247	CcSEcCtD
Valsartan—Cough—Epirubicin—liver cancer	0.000436	0.00245	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—liver cancer	0.000436	0.00245	CcSEcCtD
Valsartan—Chest pain—Epirubicin—liver cancer	0.000426	0.00239	CcSEcCtD
Valsartan—Myalgia—Epirubicin—liver cancer	0.000426	0.00239	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—liver cancer	0.000426	0.00239	CcSEcCtD
Valsartan—Anxiety—Epirubicin—liver cancer	0.000424	0.00238	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000423	0.00237	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—liver cancer	0.000416	0.00234	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—liver cancer	0.000416	0.00233	CcSEcCtD
Valsartan—Syncope—Doxorubicin—liver cancer	0.000415	0.00233	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—liver cancer	0.000409	0.00229	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—liver cancer	0.000408	0.00229	CcSEcCtD
Valsartan—Oedema—Epirubicin—liver cancer	0.000408	0.00229	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—liver cancer	0.000407	0.00228	CcSEcCtD
Valsartan—Infection—Epirubicin—liver cancer	0.000405	0.00227	CcSEcCtD
Valsartan—Cough—Doxorubicin—liver cancer	0.000404	0.00227	CcSEcCtD
Valsartan—Shock—Epirubicin—liver cancer	0.000401	0.00225	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—liver cancer	0.0004	0.00225	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—liver cancer	0.0004	0.00224	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—liver cancer	0.000396	0.00222	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—liver cancer	0.000394	0.00221	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—liver cancer	0.000394	0.00221	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—liver cancer	0.000394	0.00221	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—liver cancer	0.000392	0.0022	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000391	0.00219	CcSEcCtD
Valsartan—Anorexia—Epirubicin—liver cancer	0.000389	0.00218	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—liver cancer	0.000385	0.00216	CcSEcCtD
Valsartan—Hypotension—Epirubicin—liver cancer	0.000381	0.00214	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—liver cancer	0.000378	0.00212	CcSEcCtD
Valsartan—Oedema—Doxorubicin—liver cancer	0.000378	0.00212	CcSEcCtD
Valsartan—Infection—Doxorubicin—liver cancer	0.000375	0.0021	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000372	0.00209	CcSEcCtD
Valsartan—Shock—Doxorubicin—liver cancer	0.000371	0.00208	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—liver cancer	0.00037	0.00208	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—liver cancer	0.00037	0.00207	CcSEcCtD
Valsartan—Insomnia—Epirubicin—liver cancer	0.000369	0.00207	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—liver cancer	0.000367	0.00206	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—liver cancer	0.000366	0.00206	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—liver cancer	0.000364	0.00204	CcSEcCtD
Valsartan—Somnolence—Epirubicin—liver cancer	0.000363	0.00204	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—liver cancer	0.00036	0.00202	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—liver cancer	0.000359	0.00202	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—liver cancer	0.000355	0.00199	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—liver cancer	0.000353	0.00198	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—liver cancer	0.000352	0.00198	CcSEcCtD
Valsartan—Fatigue—Epirubicin—liver cancer	0.000352	0.00197	CcSEcCtD
Valsartan—Constipation—Epirubicin—liver cancer	0.000349	0.00196	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000344	0.00193	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—liver cancer	0.000341	0.00192	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—liver cancer	0.000339	0.0019	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—liver cancer	0.000337	0.00189	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—liver cancer	0.000336	0.00188	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—liver cancer	0.000334	0.00187	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—liver cancer	0.000332	0.00186	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—liver cancer	0.000328	0.00184	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000326	0.00183	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—liver cancer	0.000326	0.00183	CcSEcCtD
Valsartan—Urticaria—Epirubicin—liver cancer	0.000324	0.00182	CcSEcCtD
Valsartan—Constipation—Doxorubicin—liver cancer	0.000323	0.00181	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—liver cancer	0.000323	0.00181	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—liver cancer	0.000309	0.00173	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—liver cancer	0.000301	0.00169	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—liver cancer	0.0003	0.00168	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—liver cancer	0.000298	0.00167	CcSEcCtD
Valsartan—Asthenia—Epirubicin—liver cancer	0.000293	0.00164	CcSEcCtD
Valsartan—Pruritus—Epirubicin—liver cancer	0.000289	0.00162	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—liver cancer	0.000279	0.00157	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—liver cancer	0.000278	0.00156	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—liver cancer	0.000271	0.00152	CcSEcCtD
Valsartan—Dizziness—Epirubicin—liver cancer	0.00027	0.00151	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—liver cancer	0.000267	0.0015	CcSEcCtD
Valsartan—Vomiting—Epirubicin—liver cancer	0.000259	0.00146	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—liver cancer	0.000258	0.00145	CcSEcCtD
Valsartan—Rash—Epirubicin—liver cancer	0.000257	0.00144	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—liver cancer	0.000257	0.00144	CcSEcCtD
Valsartan—Headache—Epirubicin—liver cancer	0.000256	0.00143	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—liver cancer	0.00025	0.0014	CcSEcCtD
Valsartan—Nausea—Epirubicin—liver cancer	0.000242	0.00136	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—liver cancer	0.00024	0.00135	CcSEcCtD
Valsartan—Rash—Doxorubicin—liver cancer	0.000238	0.00134	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—liver cancer	0.000238	0.00133	CcSEcCtD
Valsartan—Headache—Doxorubicin—liver cancer	0.000237	0.00133	CcSEcCtD
Valsartan—Nausea—Doxorubicin—liver cancer	0.000224	0.00126	CcSEcCtD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	9.52e-05	0.000787	CbGpPWpGaD
Valsartan—ALB—Metabolism—UGDH—liver cancer	9.5e-05	0.000785	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—HMOX1—liver cancer	9.19e-05	0.000759	CbGpPWpGaD
Valsartan—ALB—Metabolism—EPT1—liver cancer	8.93e-05	0.000738	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—liver cancer	8.85e-05	0.000732	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK14—liver cancer	8.78e-05	0.000725	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADAM17—liver cancer	8.77e-05	0.000725	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	8.75e-05	0.000723	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTA4—liver cancer	8.73e-05	0.000722	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—liver cancer	8.71e-05	0.00072	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—liver cancer	8.63e-05	0.000714	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PSMA4—liver cancer	8.61e-05	0.000712	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PSMD10—liver cancer	8.61e-05	0.000712	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.53e-05	0.000705	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTA2—liver cancer	8.51e-05	0.000703	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—F2—liver cancer	8.5e-05	0.000703	CbGpPWpGaD
Valsartan—ALB—Metabolism—TAT—liver cancer	8.46e-05	0.0007	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GOT2—liver cancer	8.37e-05	0.000692	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	8.32e-05	0.000688	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—F2—liver cancer	8.27e-05	0.000684	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSMD10—liver cancer	8.25e-05	0.000682	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PSMA4—liver cancer	8.25e-05	0.000682	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—liver cancer	8.21e-05	0.000679	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTA1—liver cancer	8.21e-05	0.000679	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	8.14e-05	0.000673	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NAT2—liver cancer	8.12e-05	0.000671	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CG—liver cancer	7.91e-05	0.000654	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP2E1—liver cancer	7.87e-05	0.000651	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	7.8e-05	0.000645	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	7.8e-05	0.000644	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALDOB—liver cancer	7.78e-05	0.000643	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UGDH—liver cancer	7.77e-05	0.000643	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	7.62e-05	0.00063	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—F2—liver cancer	7.51e-05	0.000621	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—RAF1—liver cancer	7.42e-05	0.000614	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CRABP1—liver cancer	7.42e-05	0.000614	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PPARA—liver cancer	7.42e-05	0.000613	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYCS—liver cancer	7.37e-05	0.000609	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EPT1—liver cancer	7.31e-05	0.000604	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GOT1—liver cancer	7.23e-05	0.000598	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GGT1—liver cancer	7.23e-05	0.000598	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CG—liver cancer	7.19e-05	0.000594	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	7.15e-05	0.000591	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA1—liver cancer	7.14e-05	0.00059	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	7.08e-05	0.000585	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—liver cancer	7.03e-05	0.000581	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CD—liver cancer	6.96e-05	0.000575	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TAT—liver cancer	6.93e-05	0.000573	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	6.81e-05	0.000563	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.68e-05	0.000553	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTP1—liver cancer	6.49e-05	0.000537	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HPGDS—liver cancer	6.49e-05	0.000536	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.45e-05	0.000533	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMOX1—liver cancer	6.4e-05	0.000529	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCE—liver cancer	6.39e-05	0.000528	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	6.39e-05	0.000528	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CD—liver cancer	6.32e-05	0.000522	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCE—liver cancer	6.31e-05	0.000522	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	6.24e-05	0.000515	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	6.23e-05	0.000515	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CB—liver cancer	6.06e-05	0.000501	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF2—liver cancer	6.05e-05	0.000501	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	6.04e-05	0.000499	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ABL1—liver cancer	6.01e-05	0.000497	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF2—liver cancer	5.98e-05	0.000495	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTM1—liver cancer	5.97e-05	0.000493	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.88e-05	0.000486	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.8e-05	0.00048	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PSMA4—liver cancer	5.78e-05	0.000478	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PSMD10—liver cancer	5.78e-05	0.000478	CbGpPWpGaD
Valsartan—ALB—Metabolism—GLUL—liver cancer	5.75e-05	0.000476	CbGpPWpGaD
Valsartan—ALB—Metabolism—CPT1B—liver cancer	5.75e-05	0.000476	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	5.73e-05	0.000473	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1A1—liver cancer	5.66e-05	0.000468	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CSF2—liver cancer	5.65e-05	0.000467	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HGF—liver cancer	5.65e-05	0.000467	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RAF1—liver cancer	5.64e-05	0.000466	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GOT2—liver cancer	5.63e-05	0.000465	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CSF2—liver cancer	5.59e-05	0.000462	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—H2AFX—liver cancer	5.57e-05	0.000461	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—liver cancer	5.57e-05	0.00046	CbGpPWpGaD
Valsartan—ALB—Metabolism—NR1H4—liver cancer	5.55e-05	0.000459	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—liver cancer	5.52e-05	0.000456	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CB—liver cancer	5.51e-05	0.000455	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA3—liver cancer	5.45e-05	0.000451	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2E1—liver cancer	5.29e-05	0.000437	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—liver cancer	5.27e-05	0.000436	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	5.25e-05	0.000434	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARA—liver cancer	5.17e-05	0.000428	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.12e-05	0.000423	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	5.1e-05	0.000422	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—liver cancer	5.06e-05	0.000418	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—liver cancer	5.04e-05	0.000417	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA4—liver cancer	4.99e-05	0.000412	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RAF1—liver cancer	4.99e-05	0.000412	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYCS—liver cancer	4.95e-05	0.000409	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	4.88e-05	0.000403	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	4.87e-05	0.000402	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA2—liver cancer	4.86e-05	0.000402	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GGT1—liver cancer	4.86e-05	0.000401	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GOT1—liver cancer	4.86e-05	0.000401	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CPT1B—liver cancer	4.71e-05	0.000389	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GLUL—liver cancer	4.71e-05	0.000389	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA1—liver cancer	4.69e-05	0.000388	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.65e-05	0.000384	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAT2—liver cancer	4.64e-05	0.000383	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—liver cancer	4.61e-05	0.000381	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK14—liver cancer	4.58e-05	0.000378	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NR1H4—liver cancer	4.54e-05	0.000375	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK14—liver cancer	4.52e-05	0.000374	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—liver cancer	4.49e-05	0.000371	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	4.47e-05	0.000369	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA3—liver cancer	4.46e-05	0.000369	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	4.46e-05	0.000369	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDOB—liver cancer	4.45e-05	0.000368	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—F2—liver cancer	4.44e-05	0.000367	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—liver cancer	4.43e-05	0.000366	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F2—liver cancer	4.38e-05	0.000362	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—liver cancer	4.36e-05	0.000361	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—liver cancer	4.3e-05	0.000356	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—liver cancer	4.28e-05	0.000353	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—liver cancer	4.25e-05	0.000351	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APC—liver cancer	4.25e-05	0.000351	CbGpPWpGaD
Valsartan—ALB—Metabolism—CRABP1—liver cancer	4.24e-05	0.000351	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	4.24e-05	0.000351	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—liver cancer	4.19e-05	0.000347	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA4—liver cancer	4.08e-05	0.000338	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—liver cancer	4.01e-05	0.000331	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.99e-05	0.00033	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—liver cancer	3.99e-05	0.00033	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA2—liver cancer	3.98e-05	0.000329	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—liver cancer	3.89e-05	0.000322	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—liver cancer	3.84e-05	0.000318	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA1—liver cancer	3.84e-05	0.000317	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.82e-05	0.000316	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	3.8e-05	0.000314	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A1—liver cancer	3.8e-05	0.000314	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAT2—liver cancer	3.8e-05	0.000314	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—liver cancer	3.73e-05	0.000309	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPGDS—liver cancer	3.71e-05	0.000306	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—liver cancer	3.7e-05	0.000306	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—liver cancer	3.69e-05	0.000305	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—liver cancer	3.69e-05	0.000305	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.69e-05	0.000305	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—liver cancer	3.65e-05	0.000302	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.65e-05	0.000302	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—liver cancer	3.65e-05	0.000302	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDOB—liver cancer	3.64e-05	0.000301	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—liver cancer	3.54e-05	0.000293	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—liver cancer	3.48e-05	0.000287	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CRABP1—liver cancer	3.47e-05	0.000287	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—liver cancer	3.39e-05	0.000281	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	3.36e-05	0.000278	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—liver cancer	3.36e-05	0.000278	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAF1—liver cancer	3.33e-05	0.000275	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMA4—liver cancer	3.3e-05	0.000273	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMD10—liver cancer	3.3e-05	0.000273	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAF1—liver cancer	3.29e-05	0.000272	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—liver cancer	3.25e-05	0.000269	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTOR—liver cancer	3.25e-05	0.000269	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT2—liver cancer	3.21e-05	0.000266	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—liver cancer	3.21e-05	0.000266	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.13e-05	0.000258	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.12e-05	0.000258	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—liver cancer	3.11e-05	0.000257	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	3.11e-05	0.000257	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—liver cancer	3.05e-05	0.000252	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPGDS—liver cancer	3.03e-05	0.000251	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2E1—liver cancer	3.02e-05	0.00025	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—liver cancer	3.02e-05	0.00025	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3.02e-05	0.000249	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—liver cancer	2.99e-05	0.000247	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—liver cancer	2.99e-05	0.000247	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—liver cancer	2.98e-05	0.000246	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—liver cancer	2.97e-05	0.000246	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—liver cancer	2.95e-05	0.000244	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.93e-05	0.000242	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—liver cancer	2.91e-05	0.000241	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—liver cancer	2.91e-05	0.00024	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CTNNB1—liver cancer	2.88e-05	0.000238	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—liver cancer	2.87e-05	0.000237	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	2.85e-05	0.000236	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYCS—liver cancer	2.83e-05	0.000234	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—liver cancer	2.83e-05	0.000234	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—liver cancer	2.82e-05	0.000233	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT1—liver cancer	2.77e-05	0.000229	CbGpPWpGaD
Valsartan—ALB—Metabolism—GGT1—liver cancer	2.77e-05	0.000229	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK8—liver cancer	2.75e-05	0.000227	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.75e-05	0.000227	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—liver cancer	2.74e-05	0.000227	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.71e-05	0.000224	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMA4—liver cancer	2.7e-05	0.000224	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMD10—liver cancer	2.7e-05	0.000224	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT2—liver cancer	2.63e-05	0.000218	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—liver cancer	2.62e-05	0.000216	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—liver cancer	2.58e-05	0.000214	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—liver cancer	2.54e-05	0.00021	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—liver cancer	2.51e-05	0.000208	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—liver cancer	2.51e-05	0.000207	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—liver cancer	2.49e-05	0.000206	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2E1—liver cancer	2.47e-05	0.000204	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—liver cancer	2.46e-05	0.000203	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.4e-05	0.000198	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—liver cancer	2.34e-05	0.000193	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—liver cancer	2.33e-05	0.000193	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYCS—liver cancer	2.31e-05	0.000191	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—liver cancer	2.3e-05	0.00019	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—liver cancer	2.29e-05	0.000189	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—liver cancer	2.28e-05	0.000189	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GGT1—liver cancer	2.27e-05	0.000188	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT1—liver cancer	2.27e-05	0.000188	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A1—liver cancer	2.17e-05	0.000179	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—liver cancer	2.16e-05	0.000178	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—liver cancer	2.13e-05	0.000176	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—liver cancer	2.07e-05	0.000171	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—liver cancer	2.04e-05	0.000169	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—liver cancer	2.02e-05	0.000167	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—liver cancer	2.01e-05	0.000166	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—liver cancer	1.99e-05	0.000164	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—liver cancer	1.98e-05	0.000164	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—liver cancer	1.96e-05	0.000162	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—liver cancer	1.92e-05	0.000159	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—liver cancer	1.9e-05	0.000157	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—liver cancer	1.87e-05	0.000155	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—liver cancer	1.83e-05	0.000152	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—liver cancer	1.81e-05	0.00015	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.78e-05	0.000147	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A1—liver cancer	1.78e-05	0.000147	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—liver cancer	1.76e-05	0.000145	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—liver cancer	1.7e-05	0.000141	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—liver cancer	1.69e-05	0.00014	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—liver cancer	1.66e-05	0.000137	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—liver cancer	1.64e-05	0.000136	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—liver cancer	1.63e-05	0.000134	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—liver cancer	1.62e-05	0.000134	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—liver cancer	1.6e-05	0.000132	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—liver cancer	1.5e-05	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.46e-05	0.000121	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—liver cancer	1.39e-05	0.000115	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—liver cancer	1.39e-05	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—liver cancer	1.34e-05	0.000111	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—liver cancer	1.3e-05	0.000108	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—liver cancer	1.22e-05	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—liver cancer	1.21e-05	9.99e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—liver cancer	1.14e-05	9.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—liver cancer	1.07e-05	8.82e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—liver cancer	7.94e-06	6.57e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—liver cancer	6.5e-06	5.38e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—liver cancer	6.49e-06	5.36e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—liver cancer	5.31e-06	4.39e-05	CbGpPWpGaD
